🇺🇸·20h agoResearch
NCT05985954: Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Study type: INTERVENTIONAL. Phase: PHASE1.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- September 11, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE1.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
University of Minnesota/3h ago
How Minnesota Became the Front Line in the Fight Over Prediction Markets
University of Minnesota/3h ago
Why the devastating Boundary Waters wildfires are critical for a healthy Minnesota forest
University of Minnesota/3h ago
AI use is straining customer loyalty. It’s playing out in a local grocery store.
University of Minnesota/3h ago